Outcomes of patients with hematologic malignancies and COVID-19: a systematic review and meta-analysis of 3377 patientsAbi Vijenthira, Lisa K. Hicks, Inna Y. Gong et al.|Blood|2020Cited by 657
First-line treatment with zoledronic acid as compared with clodronic acid in multiple myeloma (MRC Myeloma IX): a randomised controlled trialGareth J. Morgan, J. Anthony Child, Faith E. Davies et al.|The Lancet|2010Cited by 571
Mutational Spectrum, Copy Number Changes, and Outcome: Results of a Sequencing Study of Patients With Newly Diagnosed MyelomaBrian A. Walker, Gareth J. Morgan, Alex Murison et al.|Journal of Clinical Oncology|2015Cited by 564
Minimal Residual Disease Assessed by Multiparameter Flow Cytometry in Multiple Myeloma: Impact on Outcome in the Medical Research Council Myeloma IX StudyAndy C. Rawstron, Roger G. Owen, J. A. Child et al.|Journal of Clinical Oncology|2013Cited by 419
Guidelines for the diagnosis and management of multiple myeloma 2011Jennifer M. Bird, Judith Behrens, Roger G. Owen et al.|British Journal of Haematology|2011Cited by 305